ABBV AbbVie Stock Outlook 2026: Skyrizi and Rinvoq Prove the Humira Replacement Was Real

The Humira Cliff Was Real — So Was the Recovery

When the FDA approved the first US Humira biosimilars in early 2023, AbbVie faced a wall of skepticism. Humira had been the world’s best-selling drug for years, and analysts modeled scenarios where the company would bleed out as dozens of lower-cost copies entered the market.

The bleed happened. US Humira net sales dropped from peak levels of roughly $21.2B in 2022 to approximately $9B in 2025 — a nearly 60% decline in three years. That is not a minor patent-cliff; that is an earthquake.

What surprised the market was the magnitude of the offset. Skyrizi and Rinvoq, taken together, now generate more revenue than Humira did at its height. AbbVie’s management had flagged this as the plan as far back as 2019; the execution matched the promise. For an investor assessing ABBV today, this is the central fact: the transition risk is largely behind us.

The stock currently trades at $202.71 with a market cap of $358.6B, forward P/E of 13.6x, and a 3.41% dividend yield. The 52-week range of $176.57–$244.81 shows the stock has given back meaningful ground from its highs, creating what looks like a re-entry opportunity for dividend growth investors.

---

Financial Snapshot: FY2025 and Q1 2026

Metric	Value
Stock Price (May 2026)	$202.71
Market Cap	$358.6B
FY2025 Revenue	$61.16B
FY2025 GAAP EPS	$2.36
TTM Revenue (Q1 2026)	$62.82B
Forward P/E	13.60x
Dividend Yield	3.41%
Annual Dividend/Share	$6.92
52-Week Range	$176.57 – $244.81
Consensus Target	$254.82

The gap between GAAP EPS ($2.36) and adjusted EPS (mid-$11 range) reflects the amortization of intangible assets acquired in the $63B Allergan deal — a non-cash accounting charge, not an operational loss. Forward P/E of 13.6x is calculated on the adjusted basis, which better reflects cash-generative capacity.

---

Skyrizi: From Dermatology Drug to Immunology Platform

Risankizumab (Skyrizi) is an IL-23 p19 subunit inhibitor. When it launched in 2019, most analysts modeled it as a plaque psoriasis specialist competing against IL-17 inhibitors from Novartis and Eli Lilly. The reality has been considerably broader.

FDA-approved indications:

• Plaque psoriasis (2019)
• Psoriatic arthritis (2021)
• Crohn’s disease (2022)
• Ulcerative colitis (2023)

The GI indications — Crohn’s and UC — are the growth driver. These are chronic, difficult-to-treat diseases with large addressable populations; once patients respond to a biologic, they rarely switch. Skyrizi’s clinical data in these indications has been strong enough to position it favorably against vedolizumab (Takeda) and ustekinumab (J&J’s Stelara, which faces its own biosimilar cliff).

Skyrizi revenue in 2025 exceeded $13B. AbbVie’s own guidance targets $18B+ by 2027.

---

Rinvoq: The JAK Inhibitor With a Black Box and a Growing Market Share

Upadacitinib (Rinvoq) is a JAK1-selective inhibitor. The JAK class has regulatory baggage — FDA requires a class-wide black box warning covering cardiovascular risk, malignancy, and thrombosis, based primarily on Pfizer’s tofacitinib (Xeljanz) data in higher-risk populations.

That warning has not stopped Rinvoq’s growth. Prescribers familiar with the compound’s clinical profile distinguish between the class-level warning and Rinvoq’s more selective JAK1 mechanism. Key approvals include:

• Rheumatoid arthritis
• Psoriatic arthritis
• Atopic dermatitis (competing with Dupixent in a crowded but large market)
• Ankylosing spondylitis / non-radiographic axial spondyloarthritis
• Ulcerative colitis and Crohn’s disease

Rinvoq passed $7.5B in 2025 revenue and remains one of the fastest-growing drugs in the immunology category globally.

Drug	2025 Revenue	2027 Target	Key Competitive Threats
Skyrizi	~$13B	$18B+	IL-17s (Cosentyx, Taltz), biosimilar ustekinumab
Rinvoq	~$7.5B	$11B+	Dupixent (atopic derm), other JAK inhibitors
Humira	~$9B	Declining	All biosimilars

---

Allergan: Five Years Later

The 2020 Allergan acquisition at $63B was the largest pharmaceutical deal of that era. Critics argued AbbVie overpaid for an asset-heavy aesthetics business with consumer-cycle exposure.

Five years on, the deal looks defensible.

Therapeutic Botox generates recurring, insurance-reimbursed revenue across chronic migraine, overactive bladder, and spasticity. Once a patient is established on a treatment cycle, the revenue is highly predictable. The chronic migraine indication alone serves millions of patients who have tried and failed preventive oral medications.

Cosmetic Botox and Juvederm fillers carry more discretionary risk. In 2025, slowing consumer spending and the indirect effects of GLP-1 weight-loss drugs (body composition changes affect filler demand in complex ways) created some headwinds. The Botox brand moat remains substantial — no competitor has made meaningful share gains at the premium tier.

---

Oncology: Imbruvica’s Decline and Venclexta’s Durability

Imbruvica (ibrutinib) was once AbbVie’s second-largest drug. BeiGene’s zanubrutinib (Brukinsa) has taken meaningful share in CLL and mantle cell lymphoma, citing a cleaner safety profile and comparable efficacy. Imbruvica revenue is in structural decline.

Venclexta (venetoclax), a BCL-2 inhibitor co-developed with Roche, is a different story. It remains a cornerstone of AML and CLL treatment regimens and faces no imminent competitive threat of comparable mechanism. Revenue-sharing with Roche limits AbbVie’s take, but the drug continues to grow.

---

Dividend Growth Track Record

Year	Annual Dividend	Yield (Year-End)
2020	$4.72	~5.1%
2022	$5.64	~3.8%
2024	$6.56	~3.5%
2026	$6.92	3.41%

AbbVie’s payout ratio on an adjusted EPS basis is approximately 60%, consistent with sustainable dividend growth. For dividend aristocrat investors using IRAs, the tax treatment of AbbVie’s qualified dividends makes it particularly efficient: no annual tax drag while compounding.

---

12-Month Price Target Scenarios

Scenario	Assumptions	Target Price	vs. Current
Bull	Skyrizi/Rinvoq guidance raised, Imbruvica decline moderates, neuroscience pipeline Phase 3 win	$265	+31%
Base	Consensus execution, dividend raised to $7.20, moderate Imbruvica headwind	$245	+21%
Bear	IRA negotiation expanded, Rinvoq JAK safety re-escalated, aesthetics softens materially	$175	-14%

The consensus target of $254.82 sits within the upper base/lower bull range — market-consistent.

---

Key Risks

IRA Drug Pricing: Biologic drugs become eligible for Medicare price negotiation 13 years post-approval. Skyrizi (approved 2019) hits that threshold in 2032. The actual negotiated discount and revenue impact depend heavily on future legislation, but it is a real long-term overhang.

JAK Safety Labeling: Any new safety signals from real-world Rinvoq data could prompt additional FDA action, similar to what happened with tofacitinib.

Debt Load: The Allergan acquisition left AbbVie with over $62B in long-term debt. At elevated interest rates, servicing this while maintaining dividend growth requires strong free cash flow generation — which has been delivered, but leaves limited margin for error.

Imbruvica Erosion: This is managed decline, not a new surprise, but it does create a revenue hole that Skyrizi and Rinvoq must continue to outgrow.

---

Our Take

AbbVie has done what skeptics said it couldn’t: replace Humira’s revenue with drugs that are arguably better positioned for long-term growth. The forward P/E of 13.6x on a company with $60B+ in revenue, a diversified immunology platform, a durable Botox franchise, and a 3.41% growing dividend is not an expensive valuation.

The risk profile has shifted. The Humira cliff was existential uncertainty; the current risks (IRA timelines, JAK labeling, debt) are known and manageable. For dividend growth investors, the $176 52-week low represents the downside anchor, and the $254 consensus target represents a realistic 12-month upside.

Position sizing caveat: AbbVie is not a “safe” bond substitute despite the dividend. Pharma regulation is unpredictable. Treat it as a high-quality cyclical with growing income, not a fixed-income replacement.

---

Related Healthcare Stock Analysis

• JNJ Johnson & Johnson Stock Outlook 2026
• LLY Eli Lilly Stock Outlook 2026
• PFE Pfizer Dividend & Stock Analysis
• MRK Merck Stock Outlook
• BMY Bristol-Myers Squibb Outlook